Hep C And Other High-Cost Drugs Behind 10% Rise In Canadian Medicines Spend
Executive Summary
Public drug plan spending on medicines in Canada rose by nearly 10% in 2015-16, driven by a shift to the use of expensive patented drugs such as the direct acting antivirals for hepatitis C.
You may also be interested in...
Canada Plans To Force Firms To Disclose Confidential Pricing Deals
Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.